From the Department of Neurology (E.S., K.N., V.H., D.B.) and Institute of Experimental Medicine, Medical Ethics (A.R.), Christian-Albrechts-University of Kiel; Neurological Centre (C.L., B.H.), Hospital for Movement Disorders and Parkinson's Disease, Bad Segeberg; Department of Performance, Neuroscience, Therapy and Health (B.H.), MSH-Medical School Hamburg; Department of Neurodegeneration (D.B.), Hertie Institute for Clinical Brain Research, University of Tübingen, Germany.
Neurology. 2020 May 12;94(19):e2037-e2044. doi: 10.1212/WNL.0000000000009400. Epub 2020 Apr 14.
To evaluate the point of view of patients with Parkinson disease (PD) on early detection and risk disclosure in the prodromal phase of PD and to derive recommendations for an ethical framework for the recruitment of prodromal PD cohorts.
A standardized questionnaire to evaluate the patients' perception on early diagnosis in PD was designed by an interdisciplinary study group. After testing in a preliminary feasibility study (n = 20), the survey was performed retrospectively with patients from our clinic.
A total of 101 patients with PD answered the questions. The majority of patients reported that time from onset of motor symptoms to diagnosis was burdensome, including false diagnoses and many consultations of various medical specialists. However, most of the patients evaluated early risk disclosure with skepticism. Freedom of choice and the potential of changes in lifestyle were rated as important.
Although patients with PD reported the time to diagnosis retrospectively as burdensome, the majority was skeptical regarding early disclosure of risk, especially with regard to the lack of pharmacologic options. Circumstances under which early detection and disclosure would have been approved by the majority of patients were (1) advice on lifestyle changes (exercise, nutrition) as potentially disease course-modifying therapy; (2) the establishment of an early diagnosis "culture," including early clarification of the patients' wish to know; and (3) regular support and follow-up of individuals after risk disclosure.
评估帕金森病(PD)患者对 PD 前驱期早期检测和风险披露的观点,并为前驱期 PD 队列的招募制定伦理框架建议。
一个跨学科研究小组设计了一份标准化问卷,以评估患者对 PD 早期诊断的看法。在初步可行性研究(n=20)中进行测试后,我们对来自我们诊所的患者进行了回顾性调查。
共有 101 名 PD 患者回答了这些问题。大多数患者报告说,从运动症状出现到诊断的时间很漫长,包括误诊和许多不同医学专家的咨询。然而,大多数患者对早期风险披露持怀疑态度。选择自由和改变生活方式的潜力被评为重要因素。
尽管 PD 患者回顾性地报告诊断时间很漫长,但大多数患者对早期风险披露持怀疑态度,尤其是对缺乏药物治疗选择的担忧。大多数患者可能会批准早期检测和披露的情况包括:(1)建议进行生活方式改变(运动、营养)作为潜在的疾病进程改变疗法;(2)建立早期诊断“文化”,包括早期澄清患者了解的愿望;以及(3)在风险披露后对个人进行定期支持和随访。